Business
Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, demonstrated up to 56.2% greater relative reduction in body weight on day 29 in participants with obesity (body mass index ≥ 30 kg/m2) compared to placebo in combination with semaglutide (semaglutide monotherapy).
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group.","length":331,"tagName":"p"},{"type":"text","content":"- Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47 demonstrated a lower rebound effect after treatment discontinuation compared to the semaglutide monotherapy group, supporting the potential use of once-monthly ASC47 as a maintenance therapy.","length":256,"tagName":"p"},{"type":"text","content":"HONG KONG, Sept. 21, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide, demonstrated up to 56.2% greater relative reduction in body weight on day 29 in participants with obesity (body mass index ≥ 30 kg/m2) compared to placebo in combination with semaglutide (semaglutide monotherapy).","length":424,"tagName":"p"},{"type":"text","content":"ASC47-103 study (NCT06972992), conducted in the U.S., was a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of a single-dose, ultra-long-acting subcutaneously administered ASC47 in combination with four weekly doses of 0.5 mg semaglutide in participants with obesity, compared to volume-matched placebo in combination with four weekly doses of 0.5 mg semaglutide. The treatment duration was four weeks and the follow-up period was six weeks. The study, conducted in the U.S., enrolled 28 participants with obesity. Study objectives included evaluations of safety, tolerability, pharmacokinetics, assessment of weight losses of three different single doses (10 mg, 30 mg and 60 mg) of ASC47 in combination with four weekly doses of 0.5 mg semaglutide. The effect on fat and lean mass was not an objective of this study given the short treatment duration (28 days).","length":935,"tagName":"p"},{"type":"text","content":"On day 29, a single SQ dose of 30 mg ASC47 in combination with four weekly doses of 0.5 mg semaglutide (N=6) demonstrated a 56.2% greater relative reduction in body weight compared to f...